Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

NCT04613453 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT04613453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04613453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Terminated
Start date
January 21, 2022
Completion date
December 3, 2024
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adolescent depression, adolescent suicide